Astrazeneca: How a fraud investigation crashed a FTSE 100 giant pharma Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 companies to do so. The major milestone was a testament to CEO Pascal Soriot’s strategic overhaul over the past decade, which has steered Astrazeneca away from its historic focus on respiratory and primary care toward a successful [...]
KPMG and Natwest put the CBI back in business Business Companies renew their memberships to CBI offering hope for the firm's continuation
Astrazeneca boosts cardiovascular pipeline with licensing deal pharma Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]
Astrazeneca drags down the FTSE 100 following mixed cancer trial results September 10, 2024 Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.
Google Deepmind among nominees for ‘Nobel Prize of engineering’ June 28, 2024 AI-powered weather forecasting, innovative heat batteries and the rapid manufacturing scale-up of a Covid vaccine are the three cutting edge technologies nominated for an engineering award dubbed "the Nobel Prize of Engineering".
Astrazeneca drug gets US approval for use on endometrial cancer June 17, 2024 Astrazeneca's Imfinzi drug has gained FDA approval for use on patients with primary or advanced endometrial cancer.
Astrazeneca’s revenue surges as pipeline investments pay off April 25, 2024 Pascal Soriot, chief executive officer of AstraZeneca, said: "Astrazeneca had a very strong start in 2024 with substantial total revenue growth of 19 per cent in the first quarter.
Angle agrees deal with Astrazeneca for tech to kill cancer cells April 24, 2024 This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment.